marketcap
Facebook
Twitter
Telegram
Report an ErrorQuarterly report 2023-Q3
added 11-13-2023
Eloxx Pharmaceuticals Balance Sheet 2011-2024 | ELOX
Annual Balance Sheet Eloxx Pharmaceuticals
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net Debt |
-9.94 M | -29.6 M | -19 M | -7.66 M | -48.6 M | 374 K | -811 K | -3.33 M | -6.11 M | 585 K | 198 K | -1.41 M |
Long Term Debt |
8.56 M | 12 M | 5.24 M | 10.5 M | - | - | - | - | - | - | - | - |
Long Term Debt Current |
712 K | 657 K | 389 K | 499 K | - | - | - | - | - | - | - | - |
Total Non Current Liabilities |
- | - | 5.24 M | 10.9 M | - | 2.2 M | 4.3 M | 6.54 M | 4.02 M | 99.7 K | 339 K | 811 K |
Total Current Liabilities |
23.1 M | 9.96 M | 9.84 M | 11.8 M | 7.81 M | 3.42 M | 369 K | 779 K | 1.83 M | 3.21 M | 3.16 M | - |
Total Liabilities |
31.8 M | 22.8 M | 16.2 M | 22.7 M | 7.81 M | 4.97 M | 4.67 M | 7.32 M | 5.84 M | 3.31 M | 3.5 M | 4.08 M |
Deferred Revenue |
- | - | - | 403 K | - | - | - | - | - | - | - | - |
Retained Earnings |
-274 M | -238 M | - | -137 M | -86.1 M | -122 M | -116 M | -107 M | -88.3 M | -74.4 M | -67.4 M | -60.7 M |
Total Assets |
21.1 M | 45.1 M | 26.5 M | 58.9 M | 50.7 M | 5.85 M | 9.23 M | 19.5 M | 33.3 M | 7.1 M | 6.95 M | 8.6 M |
Cash and Cash Equivalents |
19.2 M | 42.3 M | 24.7 M | 22.5 M | 48.6 M | 24 M | 2.21 M | 3.33 M | 6.11 M | 1.6 M | 2 M | 3.61 M |
Book Value |
-10.7 M | 22.4 M | 10.2 M | 36.2 M | 42.9 M | 871 K | 4.56 M | 12.2 M | 27.5 M | 3.79 M | 3.45 M | 4.52 M |
Total Shareholders Equity |
-10.7 M | 22.4 M | 10.2 M | 36.2 M | 42.9 M | 21.4 M | 610 K | 643 K | 27.5 M | 3.79 M | 3.45 M | 4.52 M |
All numbers in USD currency
Quarterly Balance Sheet Eloxx Pharmaceuticals
| 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Long Term Debt |
2.62 M | 3.33 M | 4.03 M | 8.56 M | 9.86 M | 11.1 M | 12.1 M | 12 M | 11.9 M | 3.64 M | 4.91 M | 6.38 M | 6.38 M | 6.38 M | 6.38 M | 10.5 M | 10.5 M | 10.5 M | 10.5 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Non Current Liabilities |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Liabilities |
26.1 M | 24.6 M | 23.5 M | 31.8 M | 31.9 M | 31.1 M | 31.9 M | 22.8 M | 22.4 M | 20 M | 17.6 M | 16.2 M | 16.2 M | 16.2 M | 16.2 M | 22.7 M | 22.7 M | 22.7 M | 22.7 M | 7.81 M | - | - | - | - | 3.28 M | 4.97 M | 3.26 M | 2.96 M | 3.39 M | 4.67 M | 4.67 M | 6.92 M | 6.93 M | 7.32 M | 7.32 M | 6.61 M | 5.71 M | 5.84 M | 5.84 M | 3.38 M | 3.7 M | 3.31 M | 3.31 M | 3.88 M | 3.63 M | 3.5 M | 3.5 M | 4.02 M | 4.34 M | 4.08 M | 4.08 M |
Deferred Revenue |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Retained Earnings |
-289 M | -285 M | -281 M | -274 M | -268 M | -261 M | -250 M | -238 M | -226 M | -216 M | -180 M | -172 M | -172 M | -172 M | -172 M | -137 M | -137 M | -137 M | -137 M | -86.1 M | -86.1 M | -86.1 M | -86.1 M | -39 M | -39 M | -39 M | -39 M | -17.7 M | -117 M | -117 M | -116 M | - | - | -107 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Assets |
6.04 M | 5.99 M | 7.2 M | 21.1 M | 26.9 M | 32.9 M | 43.6 M | 45.1 M | 55.4 M | 60.6 M | 20.4 M | 26.5 M | 26.5 M | 26.5 M | 26.5 M | 58.9 M | 58.9 M | 58.9 M | 58.9 M | 50.7 M | 50.7 M | 50.7 M | 50.7 M | 24.8 M | 24.8 M | 24.8 M | 24.8 M | 3.13 M | 7.01 M | 5.81 M | 9.23 M | 15.6 M | 19.4 M | 19.5 M | 19.5 M | 18.6 M | 28.1 M | 33.3 M | 33.3 M | 11.1 M | 5.81 M | 7.1 M | 7.1 M | 5.46 M | 6.26 M | 6.95 M | 6.95 M | 6.86 M | 8.27 M | 8.6 M | 8.6 M |
Cash and Cash Equivalents |
4.78 M | 4.33 M | 4.9 M | 19.2 M | 24.6 M | 30 M | 39.8 M | 42.3 M | 52.4 M | 56.7 M | 18.2 M | 24.7 M | 24.7 M | 24.7 M | 24.7 M | 22.5 M | 22.5 M | 22.5 M | 22.5 M | 48.6 M | 48.6 M | 48.6 M | 48.6 M | 24 M | 24 M | 24 M | 24 M | 2.21 M | 287 K | 149 K | 287 K | 1.37 M | 3.35 M | 2.37 M | 3.35 M | 1.74 M | 3.84 M | 2.11 M | 3.84 M | 6.12 M | 789 K | 6.12 M | 789 K | 640 K | 1.31 M | 640 K | 1.31 M | 1.55 M | 2.84 M | 1.55 M | 2.84 M |
Book Value |
-20 M | -18.6 M | -16.3 M | -10.7 M | -4.98 M | 1.81 M | 11.7 M | 22.4 M | 33 M | 40.6 M | 2.75 M | 10.2 M | 10.2 M | 10.2 M | 10.2 M | 36.2 M | 36.2 M | 36.2 M | 36.2 M | 42.9 M | 50.7 M | 50.7 M | 50.7 M | 24.8 M | 21.5 M | 19.8 M | 21.5 M | 164 K | 3.63 M | 1.14 M | 4.56 M | 8.72 M | 12.5 M | 12.2 M | 12.2 M | 11.9 M | 22.4 M | 27.5 M | 27.5 M | 7.72 M | 2.12 M | 3.79 M | 3.79 M | 1.58 M | 2.63 M | 3.45 M | 3.45 M | 2.83 M | 3.93 M | 4.52 M | 4.52 M |
Total Shareholders Equity |
-20 M | -18.6 M | 16.3 M | -10.7 M | -4.98 M | 1.81 M | 11.7 M | 22.4 M | 33 M | 40.6 M | 2.75 M | 10.2 M | 10.2 M | 10.2 M | 10.2 M | 36.2 M | 36.2 M | 36.2 M | 36.2 M | 42.9 M | 42.9 M | 42.9 M | 42.9 M | 21.4 M | 21.4 M | 21.4 M | 21.4 M | 610 K | 3.63 M | 2.84 M | 4.56 M | 643 K | 12.5 M | 8.72 M | 12.2 M | 2.78 M | 22.4 M | 11.9 M | 27.5 M | 7.72 M | 2.12 M | 3.79 M | 3.79 M | 1.58 M | 2.63 M | 3.45 M | 3.45 M | 2.83 M | 3.93 M | 4.52 M | 4.52 M |
All numbers in USD currency